25Apr 2022
Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer

Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer

Thymidine kinase 1 (TK1) recycles DNA before cell division. We do not know if baseline blood concentrations of TK1 predict death in prostate cancer within 30 years. The objective is to determine if there is an association between baseline levels of TK1 and future prostate cancer‐specific mortality. The primary endpoint was prostate cancer‐specific mortality, and outcomes after 30 years were analyzed using logistic regression modelling odds ratios (Ors). The estimated OR (adjusted for age) for dying from prostate cancer among the men who had a TK1 value in the upper tertile was 2.39 (95% confidence interval 1.02–5.63). Regardless of the cause of death, the corresponding OR was 2.81 (1.24–6.34). High levels of TK1 predict death in prostate cancer within 30 years of follow‐up.

  • #urology

Like

Save

Share